News

Patients with nAMD and their relatives experience a significant burden due to treatment-related time commitments, but most have no issues traveling to the eye clinic.

Alex Hajduczok, MD, provides perspective on the new GUIDE-HF trial data presented at HFSA 2023.

This interview with Dr. Okoye featured a discussion about her presentation at the SHSA conference, specifically regarding healthcare disparities for HS patients.

Feldman explains how healthcare legislation and regulation play a pivotal role in shaping patient care and costs.

An analysis in Denmark projects an equal increase in anti-VEGF injections given to patients with RVO and nAMD, with a minor increase for patients with DME.

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.

In this interview, Dr. Simpson discussed the latest findings presented at EADV in Berlin on the use of tapinarof cream, 1% for adults and children as young as 2 years with eczema.

Screen time ≥2 hours/day at 8 years of age was associated with an increased risk of developing IBD.

The role of psychiatric care may be understated in treating IBD in children and adolescents nearing adult age.

The risk of diabetic retinopathy appears considerably lower in SGLT2 inhibitor users than in DPP4 inhibitor users among patients with type 2 diabetes.

The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.

The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.

An update from Apellis reports 10 confirmed events of retinal vasculitis and 2 suspected events associated with pegcetacoplan injection for geographic atrophy.

Biosimilars to several recognized biologic rheumatoid arthritis treatments are now approved for use in the United States. Test your knowledge with this quiz.

In a 12-month, real-world study, the implant was effective in more than half of eyes with non-infectious uveitis, achieving effectiveness as soon as 2 weeks post-implantation.

The new data on this drug’s effects on maintenance of clinical response indicates the strength of the treatment for individuals with the immune-mediated skin disease.

More than half of patients in the mirikizumab arm achieved clinical remission at week 52.

Findings showed the probability of achieving total remission was significantly greater in the corticosteroid pulse group compared to the oral corticosteroid group.

A group of 9 experts in heart failure, ranging from leading trialists to early career clinicians, provide perspective on what they see as the biggest news in heart failure from 2023.

SGLT2 inhibitors added to metformin were associated with a significantly higher risk of diabetic retinopathy progression in the short term but significantly lower risk in the long term.

The new results from 3 different phase 3 studies presented at EADV on nemolizumab for those with prurigo nodularis and eczema show promise for the treatment.

Ahmad Masri, MD, MS, discusses long-term data from the open-label extension period of the phase 2 AG10-201 trial examining acoramidis in patients with ATTR-CM.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

Age, fecal calprotectin level, toxin B PCR cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent CDI.

On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.

Fibrosis regression was prevalent among 57% of the cohort and was associated with older age and advanced fibrosis at baseline.

This new data on the negative impacts of skin disease on individuals in 27 countries in Europe demonstrates the lasting impacts of stigmatization.

Faricimab maintained vision improvements and extended treatment intervals up to 4 months for people with RVO in the phase 3 BALATON and COMINO trials.